Climb Bio's CLYM116 Shows Superior Performance in IgA Nephropathy Preclinical Study
核心洞察
Climb Bio (搜索)'s CLYM116 demonstrated deeper IgA reduction and 2-3 times longer half-life compared to first-generation anti-APRIL (搜索) antibody sibeprenlimab in nonhuman primate studies.
The novel "sweeper" monoclonal antibody achieved >70% maximal IgA reduction with high subcutaneous bioavailability (~85%) and favorable tolerability profile.
Phase 1 trial initiation is expected in Q4 2025, targeting the estimated $10-20 billion IgA nephropathy (搜索) market in the US alone.
Climb Bio (搜索) announced promising preclinical data for CLYM116, its anti-APRIL (搜索) monoclonal antibody targeting IgA nephropathy (搜索) (IgAN), demonstrating superior pharmacokinetic and pharmacodynamic properties compared to existing therapies. The nonhuman primate study results position CLYM116 as a potential best-in-class treatment for the progressive autoimmune kidney disease.
Enhanced Therapeutic Profile Demonstrated
In head-to-head preclinical studies comparing CLYM116 to sibeprenlimab, a first-generation anti-APRIL (搜索) monoclonal antibody, CLYM116 showed significant improvements across multiple parameters. The subcutaneous formulation demonstrated high bioavailability of approximately 85% with a favorable tolerability profile.
"CLYM116 is the only known 'sweeper' anti-APRIL (搜索) monoclonal antibody in development, which we believe could provide a compelling clinical profile in IgAN," said Aoife Brennan, President and CEO of Climb Bio (搜索). The novel pH-dependent bind-and-release mechanism enables the antibody to potently block APRIL signaling, promote lysosomal degradation of APRIL, and recycle the antibody to extend its half-life.
Superior Pharmacological Performance
The preclinical data revealed prolonged exposure compared to sibeprenlimab, with a 2-3 times longer half-life across doses. After a single subcutaneous administration at equivalent doses of 6 mg/kg, CLYM116 achieved deeper and more prolonged IgA reduction compared to sibeprenlimab, with greater than 70% maximal reduction in IgA observed.
Additional in vivo studies in mice demonstrated enhanced APRIL (搜索) elimination and antibody recycling relative to sibeprenlimab, supporting the differentiated mechanism of action. These improvements translate to potential for less frequent dosing while maintaining therapeutic efficacy.
Clinical Development Timeline
Climb Bio (搜索) plans to initiate a Phase 1 trial in healthy volunteers in Q4 2025, subject to regulatory clearance. Initial data, including biomarkers and projected dosing interval information, is anticipated mid-year 2026. The company has established a parallel development program with Beijing Mabworks Biotech Co., Ltd. (搜索) in China, which is expected to provide a complementary Phase 1 dataset.
Addressing Significant Unmet Medical Need
IgA nephropathy (搜索) represents the most common primary glomerular disease worldwide, affecting approximately 170,000 patients in the US alone. The progressive autoantibody-mediated renal disease is caused by APRIL (搜索)-mediated production of pathogenic IgA and deposition of immune complexes in the glomeruli, leading to proteinuria, kidney injury, and loss of kidney function.
The disease burden is substantial, with 30-40% of patients developing kidney failure within 10 years of diagnosis. Typically diagnosed early in life, IgAN likely requires lifelong management, contributing to an estimated market opportunity of $10-20 billion in the US alone.
Regulatory Pathway and Market Opportunity
Prior product approvals in IgAN provide precedent for study design and registrational endpoints, including use of proteinuria for accelerated approval and estimated glomerular filtration rate (eGFR) for full approval. Biomarkers including APRIL (搜索) and IgA enable rapid assessment of clinical profile during early development.
The recently updated 2025 KDIGO Clinical Practice Guideline for IgAN recommends a lower threshold for biopsy to enable earlier diagnosis and stricter proteinuria control, with goals of less than 0.5 g/day, ideally less than 0.3 g/day. These guidelines may result in earlier and more aggressive disease management, potentially expanding the market opportunity for CLYM116.
Leading nephrologist Craig E. Gordon, MD, MS, who has over 20 years of experience treating IgAN patients and served as co-director of the Evidence Review Team for the 2025 KDIGO guideline, joined Climb Bio (搜索)'s management team for the investor presentation. The updated treatment guidelines highlight the importance of reducing pathogenic IgA along with managing the consequences of existing nephron loss, potentially positioning anti-APRIL (搜索) therapy as a core pillar in future IgAN treatment.